Sarcopenia Treatment Market

Sarcopenia Treatment Market Outlook (2024 to 2034)

The global sarcopenia treatment market is estimated to be valued at US$ 3.07 billion in 2024 and further increase at a CAGR of 4.2% to reach US$ 4.63 billion by 2034.

Demand for sarcopenia treatments is increasing as people are becoming conscious about their body strength. People want their bodies to be active even in old age, and they are actively looking for symptoms that may cause diseases such as sarcopenia.

Sarcopenia has been defined as an age-related, involuntary loss of skeletal muscle mass and strength. Muscle loss can lead to decreased strength, immobility, and, ultimately, adverse health outcomes. Heightened awareness has contributed to the expansion of the sarcopenia treatment market size.

Key Market Growth Drivers

• Primary cause of sarcopenia is the natural aging process. Therefore, suppliers are closely monitoring census data to identify potential buyers and enhance profitability.
• As younger generations become health-conscious, they proactively identify symptoms of sarcopenia and seek appropriate treatments, thus expanding the customer base for sarcopenia drug suppliers.
• Many individuals seek natural treatments, such as consuming fruits and vegetables, along with high-calorie, high-protein diets, to slow down muscle loss.
• Exercise has been proven to be an effective treatment for sarcopenia, often complementing drug therapies to accelerate recovery.
• Various treatment modalities, including nutritional and exercise therapy, are available, with rheumatologists tailoring treatments based on age and immune system status, further driving market growth.
• Treatment providers enhance the effectiveness of medications by incorporating compounds such as myostatin inhibitors, vitamin D, angiotensin, and omega-3 supplements, which facilitate faster strength recovery with minimal side effects, thereby boosting the demand for these treatments.

Report Attributes	Details
Sarcopenia Treatment Market Size (2024E)	US$ 3.07 Billion
Forecasted Market Value (2034F)	US$ 4.63 Billion
Global Market Growth Rate (2024 to 2034)	4.2% CAGR
Canada Market Growth Rate (2024 to 2034)	4.3% CAGR
Brazil Market Value (2034F)	US$ 72 Million
North America Market Share (2024E)	43.9%
Latin America Market Share (2034F)	2.7%
Key Companies Profiled	Bayer AG Haleon Group of Companies Zydus Life Sciences Limited Eli Lilly and Company Novartis AG Abbott Laboratories Inc. GlaxoSmithKline Plc F-Hoffmann La-Rache Sanofi Inc. Amway Corporation

How is Research on Sarcopenia and Associated Treatment Modalities Driving Market Growth?

“Increasing Studies Confirming Efficacy of Nutrient Supplementation Paired with Exercise”

Expanding scientific and technological efforts are assisting in determining the protein dose necessary to address the body's protein shortage.

• For instance, a paper published in March 2022 highlighted that protein supplementation combined with exercise improves lower-extremity strength in healthy older individuals with sarcopenia in Asian nations. Research published in PubMed in March 2022 found similar results,

Strategic initiatives by major competitors and increased awareness of the necessity of sarcopenia therapies are projected to drive market expansion during the forecast period.

• For example, World Sarcopenia Day was observed worldwide in July 2022 to increase awareness and information about the common disease sarcopenia.

Therefore, as consumers become more aware of these illnesses, the demand for protein supplements and related goods is projected to increase.

Which Sarcopenia Treatment Market Trends are Proving Beneficial for Market Players?

“Expanding Aging Population and Increased Susceptibility to Sarcopenia”

Increasing elderly population is a significant factor driving the growth of the sarcopenia treatment market due to the prevalence of sarcopenia among older individuals. The global population also is projected to continue growing, with people over 65 being one of the fastest-growing age groups worldwide.

• According to the National Institutes of Health (NIH), the global population aged 80 and above is projected to rise from 126.5 million to 446.6 million between 2015 and 2050.

Increased out-of-pocket healthcare spending is also forecast to contribute to the growing demand for sarcopenia therapy supplements.

• According to the National Health Expenditure Account (NHEA), U.S. healthcare spending rose by 4.3% percent in 2016, reaching US$ 3.3 trillion or US$ 10,348.

What Challenges Do Healthcare Practitioners Face in Diagnosing and Treating Sarcopenia?

“Lack of Standardized Diagnostic Criteria and Limited Testing Frequency”

Healthcare practitioners may not frequently test for sarcopenia, particularly in adults, limiting early intervention and treatment commencement. Without a defined diagnosis, healthcare professionals may utilize a variety of criteria and procedures to detect sarcopenia. This mismatch may result in differences in the reported prevalence of sarcopenia and the number of diagnosed cases, making it difficult to determine the real market size and demand for treatments.

Sarcopenia is a complicated disorder that affects people differently according to age, gender, and comorbidities. Patient groups may be varied, making it difficult to perform clinical trials and research to reliably evaluate therapy efficacy without defined diagnostic criteria. Clinical trials for sarcopenia therapies may employ varied diagnostic criteria, making it difficult to compare the findings of many research studies. The absence of uniformity can impede the development and approval of innovative medicines by regulatory bodies.

Country-wise Evaluation

According to an unveiled report from Fact.MR, a leading market research company, the North American region is forecast to occupy a leading sarcopenia treatment market share due to the increasing prevalence of sarcopenia among the aging population in the United States, Canada, and Mexico. The Mexico market is projected to expand at a CAGR of 4.4% from 2024 to 2034.

What Opportunities are Market Players Exploiting in the United States?

“High Health Awareness Among Public and Healthcare Providers Leading to Early Sarcopenia Diagnosis”

Attribute	United States
Market Value (2024E)	US$ 1.24 Billion
Growth Rate (2024 to 2034)	4.6% CAGR
Projected Value (2034F)	US$ 1.95 Billion

Sarcopenia is commonly linked with chronic conditions such as diabetes, cancer, and cardiovascular diseases. The growing incidence of these ailments contributes to the rising prevalence of sarcopenia in the United States, driving up the demand for treatments. This surge in cases has spurred consumers to seek therapies, thereby supporting sarcopenia treatment market growth.

Increased awareness among both the public and medical professionals in the country is leading to timely diagnosis of sarcopenia. As awareness expands, there is a growing demand for effective medications and interventions. These factors have incentivized market players to expand their businesses to capitalize on market opportunities.

Why are Sarcopenia Treatment Providers Investing in Brazil?

“Increased Prevalence of Sarcopenia Due to Low Consumption of Micronutrient-Rich Foods”

Attribute	Brazil
Market Value (2024E)	US$ 53 Million
Growth Rate (2024 to 2034)	3.1% CAGR
Projected Value (2034F)	US$ 72 Million

Micronutrient-rich foods are consumed in low quantities in developing nations like Brazil, leading to malnutrition. Sarcopenia is primarily caused by malnutrition, which is widespread in Latin America, Africa, and Southeast Asia due to poor nutritional conditions.

Rising prevalence of malnutrition leads to an increase in sarcopenia cases, resulting in a significant demand for sarcopenia therapy supplements. Vitamin D and B12 deficiencies are common among vegetarians and the elderly, serving as primary causes of sarcopenia. The growing insufficiency of vitamins is expected to fuel the demand for sarcopenia treatment supplements. As a result, Brazil has become a lucrative market for providers to capitalize on and generate substantial profits.

Category-wise Insights

Retail pharmacies are projected to account for a significant market share by 2034, and this segment is forecasted to expand at a CAGR of 13.6% from 2024 to 2034.

How are Protein Supplements Aiding in Sarcopenia Treatment?

“Vital Role of Protein Supplements in Building Muscle and Boosting Metabolism”

Attribute	Protein Supplements
Segment Value (2024E)	US$ 2.68 Billion
Growth Rate (2024 to 2034)	4.2% CAGR
Projected Value (2034F)	US$ 4.06 Billion

Protein supplements are known for building muscles, aiding weight loss, promoting better recovery, and boosting metabolism. These attributes have prompted many people to incorporate protein supplements into their routine to regain energy. Suppliers in the market have begun ramping up the production of such supplements to seize this profitable opportunity, establish dominance, and potentially create a monopoly in the market.

Which Distribution Channel is Primarily Used by Treatment Providers in the Market?

“Hypermarkets and Supermarkets Occupying Leading Market Share”

Attribute	Hypermarkets & Supermarkets
Segment Value (2024E)	US$ 917.2 Million
Growth Rate (2024 to 2034)	15.6% CAGR
Projected Value (2034F)	US$ 3.91 Billion

Hypermarkets and supermarkets have direct contact with suppliers thus they can manage to sell products at much lower prices. People always look for such low-price areas to buy quality products at much cheaper rates, thus improving the sales in the market.

Business Rivalry

Key players in the sarcopenia treatment industry are employing various strategies to enhance product penetration. Leading manufacturers in the market are focusing on innovative marketing and sales methods. Companies selling sarcopenia therapy supplements are prioritizing online product offerings and digital marketing.

• Metagenics LLC acquired 100% of Amipro Advanced Development Products in October 2023. For many years, Ampiro was the exclusive distributor of Metagenics LLC's goods in South Africa. The acquisition has enhanced Metagenics’ distribution network in the nation, allowing it to conduct direct distribution operations in all key EMEA markets.
• Biophytis was granted permission by the United States Food and Drug Administration (FDA) in September 2023 to begin its SARA-31 research in the United States. This is the first phase 3 trial in the sarcopenia therapy field.

Key Segments of Sarcopenia Treatment Market Research

• By Product Type :

  • Protein Supplements
  • Vitamin B12 Supplements
  • Vitamin D & Calcium Supplements

• By Distribution Channel :

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Hypermarkets & Supermarkets

• By Region :

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia & Oceania
  • Middle East & Africa